Lupin Ltd
Lupin Ltd (LUPIN) last traded at ₹2,174, a market capitalisation of ₹99,386 crore, on a P/E of 16.7. Over the past 52 weeks the stock has ranged between ₹1,875 and ₹2,530. Lupin Ltd last reported results for the quarter ended Jun 2026, with sales of ₹8,277 crore and net profit of ₹1,417 crore. Figures are as of 25 Aug 2026 and are not real time.
Lupin Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Lupin Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8,277 cr, up 32.1% from ₹6,268 cr a year earlier. Net profit was ₹1,417 cr, up 16.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 |
| Expenses | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 |
| Operating profit | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 |
| OPM % | 24% | 24% | 23% | 28% | 33% | 32% | 33% | 30% |
| Other income | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 |
| Interest | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 |
| Depreciation | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 |
| Profit before tax | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 |
| Tax % | 19% | 20% | 13% | 14% | 26% | 22% | 24% | 30% |
| Net profit | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 |
| EPS (₹) | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Lupin Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 | 29,967 |
| Operating profit | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 8,160 | 9,538 |
| OPM % | 17% | 1.3% | 10% | 19% | 23% | 29% | 32% |
| Net profit | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 5,355 | 5,551 |
| EPS (₹) | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 116.65 | 120.98 |
TTM is the trailing twelve months to the most recent quarter.
Lupin Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 13%
- 3 Years
- 19%
- TTM
- 28%
- 10 Years
- 10%
- 5 Years
- 37%
- 3 Years
- 140%
- TTM
- 61%
- 10 Years
- 4%
- 5 Years
- 18%
- 3 Years
- 27%
- 1 Year
- 11%
- 10 Years
- 10%
- 5 Years
- 13%
- 3 Years
- 22%
- Last Year
- 29%
Lupin Ltd shareholding pattern
Promoters held 46.85% at Jun 2026, broadly unchanged since Jun 2025. FIIs 22.42% and DIIs 24.65%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.96% | 46.94% | 46.91% | 46.90% | 46.89% | 46.89% | 46.85% | 46.85% |
| FIIs | 21.50% | 22.04% | 21.46% | 21.25% | 20.50% | 21.50% | 21.70% | 22.42% |
| DIIs | 25.10% | 24.73% | 25.41% | 25.55% | 26.56% | 25.58% | 25.32% | 24.65% |
| Government | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 6.44% | 6.27% | 6.21% | 6.28% | 6.06% | 6.04% | 6.13% | 6.08% |
| No. of shareholders | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 | 2,80,256 | 2,88,931 | 2,90,411 | 3,00,283 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Lupin Ltd corporate filings
- Intimation of allotment of 30967 equity shares under ESOP.Company Updatelow impact
Cruxal's analysis: Lupin Ltd has announced the allotment of 30,967 equity shares to employees following the…
Read the full analysis - ESG Rating by ESG Risk Assessment and Insights Limited.Company Updatelow impact
Cruxal's analysis: Lupin Ltd has provided an intimation under Regulation 30 of the SEBI (LODR) Regulations…
Read the full analysis - VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.Company Updatemedium impact
Cruxal's analysis: Lupin Ltd's wholly owned subsidiary, VISUfarma B.V. (Netherlands), has entered into an…
Read the full analysis - Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.Company Updatelow impact
Cruxal's analysis: Lupin Ltd has formally announced the passing of Dr. Sofia Mumtaz, who served as…
Read the full analysis - Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.Company Updatemedium impact
Cruxal's analysis: Lupin has secured U.S. FDA approval for Pitolisant Tablets, a medication used for the…
Read the full analysis - Transcript of Q1 FY2027 Earnings Conference CallCompany Updatehigh impact
Cruxal's analysis: Lupin Limited delivered a strong performance in Q1 FY2027, reporting total revenue of INR…
Read the full analysis - Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.Company Updatemedium impact
Cruxal's analysis: Lupin has received approval from the United States Food and Drug Administration (US FDA)…
Read the full analysis - Intimation about participating in the Analyst/Institutional Investors Meet.Company Updatelow impact
Cruxal's analysis: Lupin Ltd has issued an intimation regarding its participation in an upcoming analyst and…
Read the full analysis - Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Lupin Limited has released its unaudited financial results for the quarter ended June 30…
Read the full analysis - Link of Audio recording of the Earnings Call-Q1 FY27.Company Updatelow impact
Cruxal's analysis: Lupin Limited has formally disclosed the audio recording of its Q1 FY27 earnings call…
Read the full analysis - Investor Presentation (Revised) - Q1 FY27 ResultsCompany Updatehigh impact
Cruxal's analysis: Lupin Limited delivered a robust performance for the quarter ended June 30, 2026…
Read the full analysis - Investor Presentation- Q1 FY2027Company Updatehigh impact
Cruxal's analysis: Lupin Limited delivered a robust Q1 FY27 performance, reporting net sales of 8,217 crore…
Read the full analysis - Lupin Q1 FY2027 ResultsCompany Updatehigh impact
Cruxal's analysis: Lupin Limited reported robust Q1 FY2027 financial results with revenue from operations…
Read the full analysis - Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.Board Meetinghigh impact
Cruxal's analysis: Lupin Limited has announced its unaudited financial results for the quarter ended June…
Read the full analysis - Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.AGM/EGMlow impact
Cruxal's analysis: Lupin Limited has successfully concluded its 44th Annual General Meeting held on August…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Lupin Ltd
Cruxal reads every Lupin Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.